Form 4: Bio-Rad Executive Reports Routine Stock Transactions Following RSU Vesting

Bio-Rad Laboratories EVP Eva Anette Engelhardt reported the acquisition of 245 shares of Class A common stock from restricted stock unit vesting and the disposition of 88 shares for tax purposes.

Summary

• Eva Anette Engelhardt, EVP, President, CDG of Bio-Rad Laboratories, Inc., reported transactions on July 25, 2025.
• Acquired 245 shares of Bio-Rad Class A Common Stock through the vesting of restricted stock units at a price of $0.
• Disposed of 88 shares of Bio-Rad Class A Common Stock at a price of $264.19, likely for tax withholding related to the vesting.
• Following these transactions, direct beneficial ownership of Bio-Rad Class A Common Stock is 157 shares.
• Direct beneficial ownership of derivative securities (Restricted Stock Units) is 738 units.
• Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
• Restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.

Sentiment

Score: 6

Explanation: The filing reports routine executive compensation activities, specifically the vesting of restricted stock units and subsequent tax-related share disposition. This is a neutral event, but the vesting itself is a positive sign of executive retention and alignment.

Positives

• Vesting of restricted stock units indicates the executive is meeting performance or tenure requirements, aligning executive interests with shareholder value.

Negatives

• Disposition of 88 shares, though for tax withholding, reduces the executive's direct shareholding.

Future Outlook

Restricted stock units are structured to vest over four years at 25% per year on the yearly anniversary date of the grant, indicating future potential share acquisitions for the executive.

Industry Context

This filing reflects standard executive compensation practices within the biotechnology and life sciences industry, where restricted stock units are commonly used to incentivize and retain key personnel.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) with a multi-year vesting schedule is a common compensation practice for executives across various industries, including biotechnology, aligning executive incentives with long-term company performance.

Related Party Transactions

• The vesting of restricted stock units and subsequent share disposition for tax purposes are transactions between the company and a key executive, which are considered related-party transactions in the context of executive compensation.

Stakeholder Impact

• Shareholders: The vesting of restricted stock units aligns the executive's long-term interests with shareholder value, as the executive gains ownership in the company.
• Employees: Reflects standard executive compensation practices, potentially signaling stability in leadership.

Next Steps

• Continued vesting of the remaining 738 restricted stock units over the next four years at 25% per year on the yearly anniversary date of the grant.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, specifically the vesting of restricted stock units and subsequent tax-related share disposition. Such transactions are standard and generally do not indicate a significant change in the company's fundamental outlook or operations. Therefore, a 'hold' recommendation is appropriate as this filing does not provide new information warranting a change in investment thesis.

Keywords

Bio-Rad, SEC Form 4, insider transaction, executive compensation, restricted stock units, RSU vesting, common stock, stock disposition, tax withholding